



Recruiting Myelofibrosis Trials	
<p>ACE-536-MF-001 (Interventional) Myelofibrosis</p> <p>PI: Prof Adam Mead</p>	<p>A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with MPN-Associated Myelofibrosis and Anemia with or without Red Blood Cell-Transfusion Dependence</p> <p>Eligibility Criteria: Age 18 or over, Subject has MPN-associated myelofibrosis, Subject has anaemia and an ECOG performance score ≤ 2. Includes patients currently on ruxolitinib, but may also not be on the drug</p>
<p>KRT-232-101 (Interventional) Myelofibrosis</p> <p>PI: Prof Adam Mead</p>	<p>An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With PMF, PPV-MF, Or PET-MF Who Have Failed Ruxolitinib</p> <p>Eligibility Criteria: Age 18 or over, Diagnosis of PMF, PPV-MF, PET-MF, Palpable splenomegaly ≥ 5cm, DIPSS \geq Intermediate-1, ECOG performance status ≤ 2 with adequate end organ function, Prior ruxolitinib treatment failure</p>
<p>MANIFEST (Interventional) Myelofibrosis</p> <p>PI: Prof Adam Mead</p>	<p>A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)</p> <p>Eligibility Criteria: Age 18 and over, Phase 2: Diagnosis of MF, DIPSS \geq Intermediate-1, ECOG performance status ≤ 2 with adequate end organ function, Palpable splenomegaly ≥ 5cm OR RBC transfusion dependent, At least 2 symptoms measurable, ANC $\geq 1 \times 10^9/L$, Platelet count $\geq 75 \times 10^9/L$</p>
<p>TAMARIN (Interventional) All MPN</p> <p>PI: Prof Adam Mead</p>	<p>Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms</p> <p>Eligibility Criteria: PV,ET,MF, Stable disease on hydroxyurea, interferon or ruxolitinib, No prior thrombosis, Age over 60, men aged between 50-59 may be considered, women must be post-menopausal</p>
<p>PHAZAR (Interventional) Accelerated or blast phase MPN</p> <p>PI: Prof Adam Mead</p>	<p>A Phase 1b Study to assess the safety and tolerability of oral Ruxolitinib in combination with Azacitidine in patients with Advanced Phase MPN, including MDS or AML arising from MPN</p> <p>Eligibility Criteria: Age 16 and over, Diagnosis of ET,PV or MF with $> 10\%$ bone marrow blasts (with or without dysplastic changes), ECOG performance status ≤ 3</p>

<p>MEASURES (Non-interventional) All MPN</p> <p>PI: Prof Adam Mead</p>	<p>The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) Trial: Serial Assessment of Symptomatic Response to Non Experimental Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms</p> <p>Eligibility Criteria: All Ph- MPN patients starting a new, therapeutic intervention</p>
<p>INForMeD (Non-interventional) All MPN</p> <p>PI: Prof Adam Mead</p>	<p>An observational and biological research study to investigate the genetic and cellular basis of sporadic and familial myeloid disorders</p> <p>Eligibility Criteria: Age 2 or over, Patients under investigation for or diagnosed with a myeloid or related disorder, Patient willing to give consent to the study</p>

Haematology Research contact details	
Prof Adam Mead	Email: adam.mead@imm.ox.ac.uk Tel: 01865 222324
Research Nurse Team	Email: LP.haematology.RN@oxnet.nhs.uk